ArticleAnnals of hematology2021

Ruxolitinib is an effective salvage treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation without posttransplant cyclophosphamide.

Jiao-Yu Zhao et al.PubMed ↗Publisher ↗

No numbers read from the abstract.